title: Psoriasis disappearance after the first phase of an oncologic treatment: a serendipity case report.
abstract: Psoriasis is a multifaceted disorder with psychosocial and physical aspects that negatively impact the quality of life. Strategies of treatment must address both rapid control of the disease and maintenance of benefits. For short and long-term control of localized psoriasis, recent data support the combined use of topical corticosteroids and either calcipotriene or tazarotene which seem to be the most effective approach. For generalized disease, UVB treatment provides the safest means of achieving long-term control of the disease. Acitretin is a very helpful adjunct for improving the efficacy of phototherapy. For patients with severe, refractory disease, methotrexate may be most effective while cyclosporine may be most valuable for patients needing rapid, short-term improvement. Other molecules, with different pharmacological properties, are actually under consideration. Herein it is reported a case of a 55 year old male, who refers, 2 weeks after the fi rst cycle of oncologic therapy with gemcitabine and cisplatin for a lung neoplasm, about the complete remission of the psoriasis on both fingernails and scalp, suffered since almost ten years. Three months after the fortuitous detection of the psoriasis disappearance, there is no further evidence of psoriatic lesions.
authors.affiliation: Department of Pharmacology, Medical Faculty, University of Bari, Italy. r.cagiano@farmacol.uniba.it
authors.forename: R
authors.initials: R
authors.lastname: Cagiano
authors.forename: I
authors.initials: I
authors.lastname: Bera
authors.forename: D
authors.initials: D
authors.lastname: Vermesan
authors.forename: P
authors.initials: P
authors.lastname: Flace
authors.forename: R
authors.initials: R
authors.lastname: Sabatini
authors.forename: L
authors.initials: L
authors.lastname: Bottalico
authors.forename: P
authors.initials: P
authors.lastname: Auteri
authors.forename: L
authors.initials: L
authors.lastname: Santacroce
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D004249:DNA Damage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D011701:PUVA Therapy; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000523:psychology / Q000628:therapy; D013315:Stress, Psychological / Q000150:complications; D014467:Ultraviolet Therapy; D000093542:Gemcitabine
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine